Follicular lymphoma: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• CD19 27
• CD20 14
• BTK 9
• BCL-2 5
• CD22 5
• MYC 3
• EZH2 2
• PD-1 3
• PI3K 0
• PD-L1 1
• TP53 0
• CD40 0
• CD47 0
• CXCR4 0
• EGFR 0
• HDAC 0
• ABL1 0
• AKT 0
• ALK 0
• BRAF 0
• BRCA1 1
• BRCA2 1
• CCR5 0
• CD30 0
• CSF1R 1
• G6PD 0
• IL-1 0
• IL-15 0
• IL-17 0
• LAG-3 0
• MEK 0
• PPAR 0
• STAT3 0
• TFEB 0
• TIGIT 1
• TIM-3 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 32+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

  NCT05828589· BeOne Medicines· Updated 14 Jul 2026

  “This decision is due to a company business decision with strategy change on the BGB-21447 development in B-cell malignancies and is not driven by safety concerns.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

  NCT06806033· Hoffmann-La Roche· Source

• Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

  NCT04799275· National Cancer Institute (NCI)· Source

• A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

  NCT05828589· BeOne Medicines· Source

• Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

  NCT05583149· Patrick C. Johnson, MD· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 4
• Mendelian Randomization Analysis 2
• CRISPR-Cas Systems 1
• Gene Expression Profiling 5
• Whole Genome Sequencing 1
• Flow Cytometry 2
• Immunohistochemistry 12
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 1
• Machine Learning 2
• Deep Learning 2
• Cohort Studies 6
• Genome-Wide Association Study 4

• A deep learning PET/CT biomarker for early progression (POD24) and survival stratification in follicular lymphoma: a multicenter study.

  Eur J Nucl Med Mol Imaging, Mar 2026

• Interpretable deep learning radiomics from 18F-FDG PET/CT for differentiating diffuse large B-cell lymphoma and follicular lymphoma.

  BMC Med Imaging, Mar 2026

See which targets of this disease your abstract mentions, and go to the people working on them.